Sionna Therapeutics, Inc.
NASDAQ:SIONBiotechnology
+$0.68 today
- Market cap
- $134.35M
- Beta
- 1.29
- P/E (TTM)
- -19.7
- EPS (TTM)
- -$1.90
Volume 0.52M
Average 0.39M
SION Weighted Avg Shares
Average number of basic shares outstanding during the period, used to calculate basic EPS.
Sionna Therapeutics, Inc.NASDAQ: SION
Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026
Weighted avg shares growth accelerates
Q1 FY2026 weighted avg shares of 44.92M shares rose 1.9% year over year, ahead of the -1.7% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 12.4% from the prior quarter. Over 3 fiscal years it compounded at -3.2% a year.
Context
- Weighted avg shares increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +1.9% holds above the trailing-twelve-month pace of -1.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares history
Shares · from the income statement
- Latest · FY2025
- 39.96M USD
- Year-over-year change
- -9.4%
- 3-year CAGR
- -3.2%
| Period | Period end | Weighted Avg Shares | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 39.96M | -9.4% |
| FY2024 | 2024-12-31 | 44.12M | +0.0% |
| FY2023 | 2023-12-31 | 44.12M | +0.0% |
| FY2022 | 2022-12-31 | 44.12M | — |
Weighted Avg Shares vs competitors
How SION compares with its peers on the latest reported figures
- SION's LTM Mar 2026 weighted avg shares of 43.37M shares is the lowest of the 11 companies compared; the peer median is 90.24M shares.
- Its year-over-year change of -1.7% is the 10th highest of 11, against a peer median of +9.1%.
- Over three fiscal years its annual growth of -3.2% compares with a peer median of +13.3%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Sep 2026 | 306.35M | +3.0% | +1.6% | |
| LTM Mar 2026 | 242.83M | +2.6% | +15.0% | |
| LTM Mar 2026 | 167.52M | +11.9% | +5.8% | |
| LTM Jun 2026 | 131.06M | +31.1% | +34.0% | |
| LTM Sep 2026 | 106.83M | +34.8% | +93.1% | |
| LTM Sep 2026 | 73.65M | -2.5% | +4.9% | |
| LTM Sep 2026 | 72.36M | +9.0% | +12.4% | |
| LTM Jun 2026 | 67.85M | +14.4% | +34.2% | |
| LTM Mar 2026 | 62.14M | +9.2% | +14.3% | |
| LTM Mar 2026 | 46.63M | +6.5% | -0.6% | |
| LTM Mar 2026 | 43.37M | -1.7% | -3.2% | |
| Peer median (excluding SION) | 90.24M | +9.1% | +13.3% | |
Competitors are the stored peer set for SION. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 668K | 647K |
| Gross Profit | 0 | 0 | (668K) | (647K) |
| Gross Margin | — | — | — | — |
| Research & Development | 34.61M | 40.63M | 57.29M | 60.26M |
| Selling, General & Admin | 6.77M | 9.71M | 13.27M | 28.72M |
| Operating Expenses | 41.37M | 50.33M | 69.89M | 88.34M |
| Depreciation & Amortization | 122K | 583K | 668K | 647K |
| EBITDA | (40.12M) | (46.68M) | (61.02M) | (74.62M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (41.37M) | (50.33M) | (70.56M) | (88.98M) |
| Operating Margin | — | — | — | — |
| Interest Income | 1.13M | 2.77M | 8.17M | 13.3M |
| Interest Expense | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 1.13M | 3.07M | 8.87M | 13.71M |
| Income Before Tax | (40.24M) | (47.26M) | (61.69M) | (75.27M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Net Income | (40.24M) | (47.26M) | (61.69M) | (75.27M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (0.91) | (1.07) | (1.40) | (1.88) |
| EPS (Diluted) | (0.91) | (1.07) | (1.40) | (1.88) |
| Weighted Avg Shares | 44.12M | 44.12M | 44.12M | 39.96M |
| Weighted Avg Shares (Diluted) | 44.12M | 44.12M | 44.12M | 39.96M |
Sionna Therapeutics, Inc.
NASDAQ:SION
Intrinsic Alpha fair value
Locked
Current Price
$2.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.